US Stock Insider Trading | Doximity disclosed four insider transactions on February 18

2026-02-20 18:27:20

On February 18, 2026, Doximity (DOCS) disclosed four insider trading transactions. Executive Bryson Anna sold 11,400 shares on February 15, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Executive	Sitaram Siddharth	February 15, 2026	Sell	946	25.02	23,700
February 18, 2026	Executive	Bryson Anna	February 15, 2026	Sell	11,400	25.02	284,800
February 18, 2026	Executive	Sitaram Siddharth	February 15, 2026	Buy	384	21.27	8,166.53
February 18, 2026	Shareholder with over 10%	Jeffrey Tangney	February 15, 2026	Sell	8,243	25.02	206,200
February 4, 2026	Director	Kira Scherer Wampler	February 2, 2026	Sell	2,000	37.33	74,700
January 6, 2026	Director	Kira Scherer Wampler	January 2, 2026	Sell	2,000	44.65	89,300
December 3, 2025	Director	Kira Scherer Wampler	December 1, 2025	Sell	2,000	50.71	101,400
November 24, 2025	Director	Timothy S. Cabral	November 21, 2025	Sell	10,000	50.00	500,000
November 18, 2025	Executive	Bryson Anna	November 15, 2025	Sell	5,121	49.62	254,100
November 18, 2025	Shareholder with over 10%	Jeffrey Tangney	November 15, 2025	Sell	8,005	49.62	397,200

[Company Information]

Doximity, Inc. was incorporated in Delaware in April 2010. It is a leading digital platform for healthcare professionals in the United States. As of March 31, 2021, it had over 1.8 million healthcare professional members, including physicians from all 50 states and over 80% of doctors in each medical specialty. The cloud-based platform provides tools specifically built for medical professionals, enabling collaboration with colleagues, secure patient care coordination, virtual patient visits, timely access to the latest medical news and research, and career management.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes